Michael J. Wick
4 Papers
12 Citations
Michael J. Wick is an academic researcher. The author has contributed to research in topics: Adenoid cystic carcinoma & MYB. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma
Yotam Drier,Yotam Drier,Yotam Drier,Matthew J. Cotton,Matthew J. Cotton,Matthew J. Cotton,Kaylyn E. Williamson,Kaylyn E. Williamson,Kaylyn E. Williamson,Shawn M. Gillespie,Shawn M. Gillespie,Shawn M. Gillespie,Russell J.H. Ryan,Russell J.H. Ryan,Russell J.H. Ryan,Michael J. Kluk,Christopher D. Carey,Scott J. Rodig,Lynette M. Sholl,A. Afrogheh,William C. Faquin,Lurdes Queimado,Jun Qi,Michael J. Wick,Adel K. El-Naggar,James E. Bradner,James E. Bradner,Christopher A. Moskaluk,Jon C. Aster,Birgit Knoechel,Birgit Knoechel,Bradley E. Bernstein,Bradley E. Bernstein,Bradley E. Bernstein +33 more
TL;DR: This study identifies super-enhancer translocations that drive MYB expression and provides insight into downstream MYB functions in alternate ACC lineages.
Zebrafish blastomere screen identifies retinoic acid suppression of MYB in adenoid cystic carcinoma.
Joseph Mandelbaum,Ilya Shestopalov,Rachel E. Henderson,Nicole G. Chau,Birgit Knoechel,Michael J. Wick,Leonard I. Zon +6 more
TL;DR: The zebrafish pluripotent cell culture system is established as a method to identify modulators of tumor formation, particularly establishing retinoic acid as a potential new effective therapy for ACC.
A multiplex preclinical model for adenoid cystic carcinoma of the salivary gland identifies regorafenib as a potential therapeutic drug.
Chen Chen,Sujata Choudhury,Darawalee Wangsa,Chamille J. Lescott,Devan J. Wilkins,Praathibha Sripadhan,Xuefeng Liu,Danny Wangsa,Thomas Ried,Christopher A. Moskaluk,Michael J. Wick,Eric Glasgow,Richard Schlegel,Seema Agarwal +13 more
TL;DR: The CR/zebrafish model mirrors the PDX mouse model and identifies regorafenib as a potential therapeutic drug to treat this cancer type that mimic the drug sensitivity profile in PDX model, further confirming the unique advantages of multiplex system.
45
Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma
Kristy A. Warner,Felipe Nör,Gerson Arisoly Xavier Acasigua,Manoela Domingues Martins,Zhaocheng Zhang,Scott A. McLean,Matthew E. Spector,Douglas B. Chepeha,Joseph I. Helman,Michael J. Wick,Christopher A. Moskaluk,Rogerio M. Castilho,Alexander T. Pearson,Shaomeng Wang,Jacques E. Nör +14 more
TL;DR: It is demonstrated that therapeutic inhibition of the MDM2–p53 interaction with MI-773 activates downstream effectors of apoptosis and causes robust tumor regression in preclinical models of ACC.